The Journal of the American Medical Association Finds Myocarditis and Pericarditis Caused by mRNA Vaccine

Published in Scientific Evidence - Last Updated February 7, 2022

A new study published on Tuesday, January 25, 2022, in the Journal of the American Medical Association (JAMA), revealed that mRNA-based COVID-19 vaccination triggered the development of myocarditis and pericarditis. It is most common among adolescent males and young men.

The study was based on the data from VAERS on reported cases of myocarditis that occurred after receiving the Pfizer and Moderna vaccine between December 2020 and August 2021 in 192,405,448 individuals older than 12 years of age in the US. As of September 30, 2021, the data was processed by VAERS.

Myocarditis and pericarditis were the major findings after vaccination.

According to the research, VAERS received 1,991 reports of myocarditis (391 of which also included pericarditis) after receiving at least one dose of mRNA-based COVID-19 vaccine, and 684 reports of pericarditis without the presence of myocarditis.

1,626 of the 1,991 heart disease reports met the CDC’s case definition for probable or confirmed myocarditis.

Only 3% of the samples were J&J and 98% were mRNA. Although uncommon, it has also been discovered in women, girls, and older individuals.

Despite the fact that it is ‘rare,’ should a ‘vaccine’ be mandated if it can lead to cardiac problems for the individual who receives it?

From the Abstract

Key Points

Question:  What is the chance of myocarditis after mRNA-based COVID-19 immunization in the United States?

Findings:  Within 7 days after vaccination, the crude reporting rates in this descriptive study of 1626 myocarditis cases in a national passive reporting system, exceeded the predicted rates across many age and sex categories.

• In adolescent males aged 12 to 15 years, the rates of myocarditis were highest after the second vaccination dose (70.7 per million doses of the BNT162b2 vaccine)
• Adolescent males aged 16 to 17 years have a vaccine-derived risk of 105.9 cases per million doses of the BNT162b2 vaccination
• And in males aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively)

Meaning:  The risk of myocarditis increased in all age and sex categories when the mRNA-based COVID-19 vaccines were given, according to passive surveillance data from the United States. After the second vaccination dose, adolescent males and young men had a higher risk of myocarditis than other age groups.

Complete Study